Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis by Pooja M Dhupkar et al.
POSTER PRESENTATION Open Access
Immune modulation through targeting PD-1/PDL-1
signaling pathway for the treatment of
osteosarcoma lung metastastasis
Pooja M Dhupkar1*, Ling Yu2, Nancy Gordon2, Eugenie S Kleinerman2
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Osteosarcoma (OS) is a primary bone malignancy, com-
monly culminating into aggressive pulmonary metastasis.
Despite chemotherapy advances, the 5-year survival of
pulmonary metastatic OS remains 25-30%. Immunother-
apy is one of the promising novel approaches to target
minimal residual and relapsed disease. Previously, we
have demonstrated that Liposomal muramyl tripeptipe
phosphatidyl ethanolamine (L-MTP-PE), through a
mechanism that involves macrophage activation, reduced
the metastatic burden in animal models and caused an
8% improvement in the overall survival of patients with
OS metastatic disease.
The goal of this study is to determine if PD-1-PDL-1
immunosuppressive signaling pathway can be targeted
using PD-1 checkpoint inhibitors against OS lung
metastasis. Upregulation of PDL-1 on tumor cells and
its enhanced interaction with PD-1 immune-inhibitory
receptor is one of the acquired mechanisms of tumor cells
to decrease immune-therapeutic efficacy. Anti-PD-1 and
anti-PDL-1 antibodies have exhibited therapeutic benefit
in melanoma, renal cell carcinoma and non-small cell lung
carcinoma. However, the effect of anti-PD-1 therapy and
the role of PD-1-PDL-1 signaling in metastatic OS lung
disease have not been investigated. We hypothesize that
the disruption of the PD-1-PDL-1 signaling pathway using
anti-PD-1 antibody is effective against OS lung metastasis
and will improve the overall survival. Our data confirms
surface and total PD-L1 expression in a panel of human
OS cell lines by flow cytometry and Western blot analyses
respectively. Furthermore, immunohistochemistry staining
of primary and metastatic lung tumor samples from
patients demonstrated membranous and cytoplasmic
PDL-1 expression providing evidence that PDL-1 might be
responsible to the limited OS response to immunotherapy.
In addition, using a human OS mouse model we demon-
strated therapeutic effect of anti-PD-1 therapy as
evidenced by a decrease in the number of micro and
macrometastases. Immunohistochemistry staining of lung
tissues from mice treated with anti-PD-1 therapy demon-
strated enhanced macrophage infiltration when compared
with the control group. However, there was no significant
increase in NK cell infiltration. We further demonstrated a
decrease in PDL-1, p-ER1/2 and p-Stat-3 expression by
Western blot analyses of lung tumors from mice receiving
anti-PD-1 treatment. We conclude that anti-PD-1 thera-
peutic efficacy may be mediated by the enhanced macro-
phage infiltration in osteosarcoma pulmonary metastatic
tumors. Targeting PD-1/PD-L1 axis might be a promising
approach for the treatment of OS lung metastasis.
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